GPC Biotech AG (NASDAQ: GPCB), a biopharmaceutical company, is focused on discovering, developing, and commercializing anticancer drugs. Its pipeline of products include satraplatin, an oral platinum-based anticancer agent that is in phase 1 and 2 trials; RGB-286638, a broad-spectrum kinase inhibitor that has completed pre-clinical testing; and RGB-344064, a selective inhibitor of cyclin-dependent kinases that is in pre-clinical testing. For further information, visit the Company’s web site at www.gpc-biotech.com.
- 18 years ago
QualityStocks
GPC Biotech AG (NASDAQ: GPCB)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…